drugset / Trial / NCT03939975
Anti-PD-1therapy Combined With Thermal Ablation for Advanced HCC
NaSingle-groupOpen-labelTreatment
Summary
The inhibition of programmed cell death protein 1 (PD-1) has shown promising antitumor activity in advanced hepatocellular carcinoma (HCC). Unfortunately, less than 20% of HCC have response. The effect of PD-1 blockade and incomplete thermal ablation in patients with advanced HCC is not yet clearly understood. This study aimed to analyze outcomes of advanced HCC treated with anti PD-1 inhibitors in combination with incomplete thermal ablation.
Timeline
- Start
- 2019-06-01
- Primary completion
- 2019-07-31
- Completion
- 2019-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 3 mg/kg | — |
| Subject | Pembrolizumab | Monoclonal antibody | 2 mg/kg | — |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | — |